×
About 38,710 results

ALLMedicine™ Myeloid Leukemia Center

Research & Reviews  13,246 results

Distribution and frequency of tyrosine kinase inhibitor-associated long-term complicati...
https://doi.org/10.1002/pbc.29786
Pediatric Blood & Cancer; Dong EE, Bruno MA et. al.

May 21st, 2022 - Tyrosine kinase inhibitors (TKIs) improve outcomes for pediatric malignancies characterized by specific gene rearrangements and mutations; however, little is known about the long-term impact of TKI exposure. Our objective was to assess the inciden...

Preinduction Serum Vitamin D3 Levels and Induction Chemotherapy Remission Rates in Pati...
https://doi.org/10.1080/01635581.2022.2077389
Nutrition and Cancer; Maurya S, Tripathi AK et. al.

May 21st, 2022 - Vitamin D deficiency(<20 ng/mL) is a common condition, associated with an inferior prognosis in some cancers. However, the prognostic significance of vitamin D deficiency in acute leukemia is largely unknown. The present study aimed to assess the ...

Leukemic Stem Cells as a Target for Eliminating Acute Myeloid Leukemia: Gaps in Transla...
https://doi.org/10.1016/j.critrevonc.2022.103710
Critical Reviews in Oncology/hematology; Khaldoyanidi SK, Hindoyan A et. al.

May 20th, 2022 - Relapse is common in acute myeloid leukemia (AML) and thought to be due to resistance of underlying leukemic stem cells (LSCs) to current standard therapies, although a lack of tools to measure the quantity and quality of these cells in patients p...

Prevalence and natural history of variants in the ANKRD26 gene: a short review and upda...
https://doi.org/10.1080/09537104.2022.2071853
Platelets Vyas H, Alcheikh A et. al.

May 20th, 2022 - ANKRD26 is a highly conserved gene located on chromosome 10p12.1 which has shown to play a role in normal megakaryocyte differentiation. ANKRD26-related thrombocytopenia, or thrombocytopenia 2, is an inherited thrombocytopenia with mild bleeding d...

see more →

Guidelines  16 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2020.0047
Journal of the National Comprehensive Cancer Network : JN... Deininger MW, Shah NP et. al.

Oct 7th, 2020 - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phas...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients W...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499615
Journal of Clinical Oncology : Official Journal of the Am... Lehrnbecher T, Fisher BT et. al.

May 28th, 2020 - To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. Recommendations were developed by an international multidisciplinary pane...

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendati...
https://doi.org/10.1002/cncr.31411
Cancer Rea D, Ame S et. al.

May 4th, 2018 - The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off-treatment response after treatment discontinuation; this situation is...

see more →

Drugs  80 results see all →

Clinicaltrials.gov  616 results

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
https://clinicaltrials.gov/ct2/show/NCT04304820

May 20th, 2022 - Severe aplastic anemia (SAA) is a life-threatening bone marrow failure characterized by pancytopenia and a hypocellular marrow. Allogeneic bone marrow transplantation is curative in younger patients, but older age and/or lack of a suitable donor h...

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
https://clinicaltrials.gov/ct2/show/NCT03560882

May 19th, 2022 - This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in malignant diseases (solid ...

A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies
https://clinicaltrials.gov/ct2/show/NCT03530683

May 19th, 2022 - This is a trial of TTI-622 in subjects with relapsed or refractory lymphoma or multiple myeloma (MM) and subjects with newly diagnosed acute myeloid leukemia (AML). This trial will be conducted in 2 phases: Phase 1a (Dose-Escalation Phase for Sing...

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
https://clinicaltrials.gov/ct2/show/NCT03896854

May 19th, 2022 - The patients will receive infusion of CART cells targeting CD19 to confirm the safety and efficacy of CD19 CART Cells in relapsed or refractory acute myeloid leukemia.

Quality of Life Model for Older Patients With AML
https://clinicaltrials.gov/ct2/show/NCT04380441

May 19th, 2022 - The purpose of this study is to describe the differences in quality of life (QOL) among newly diagnosed patients diagnosed with acute myeloid leukemia (AML) to help design a patient decision-making QOL model for aligning patients' choice of treatm...

see more →

News  1,520 results

Intermediate-Risk Acute Myeloid Leukemia
https://www.medscape.com/viewarticle/964532

May 19th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York Ci...

Venetoclax Add-On Promising in Newly Diagnosed AML
https://www.medscape.com/viewarticle/973769

May 12th, 2022 - NEW YORK (Reuters Health) - Adding venetoclax to the conventional induction with daunorubicine and cytarabine ("DA" regimen) led to high rates of complete remission in adults with newly diagnosed acute myeloid leukemia (AML) in a study conducted i...

FDA Lifts Partial Clinical Hold Placed on Studies Evaluating Magrolimab in MDS and AML
https://www.onclive.com/view/fda-lifts-partial-clinical-hold-placed-on-studies-evaluating-magrolimab-in-mds-and-aml

May 7th, 2022 - The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial, according to an announcement from Gilead Sci...

FDA Grants Fast Track Status to PRGN-3006 for Relapsed/Refractory AML
https://www.onclive.com/view/fda-grants-fast-track-status-to-prgn-3006-for-relapsed-refractory-aml

May 2nd, 2022 - The FDA has granted a fast track designation to the multigenic autologous CAR T-cell therapy PRGN-3006 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia (AML), according to an announcement fro...

Microbiota Modulation Offers Hope of Expanding the Benefits of Immunotherapy
https://www.onclive.com/view/microbiota-modulation-offers-hope-of-expanding-the-benefits-of-immunotherapy

Apr 28th, 2022 - Although the microorganisms colonizing our bodies have long been linked to human health and various disease states, an understanding of the potential impact of the microbiota on cancer has just begun to emerge in the past 20 years. Novel strategie...

see more →

Patient Education  6 results see all →